# A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

> **NCT01876771** · PHASE2 · RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 500 (estimated)

## Conditions studied

- Carcinoma, Neuroendocrine

## Interventions

- **DRUG:** [177]Lu-DOTA-TATE

## Key facts

- **NCT ID:** NCT01876771
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-04-29
- **Primary completion:** 2042-12
- **Final completion:** 2042-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876771, "A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01876771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*